Definitive Healthcare (NASDAQ:DH) Releases Q4 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its fourth quarter 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.070-0.070 for the period, compared to the consensus estimate of 0.070. The company issued revenue guidance of $60.0 million-$61.0 million, compared to the consensus revenue estimate of $60.3 million. Definitive Healthcare also updated its FY 2024 guidance to 0.340-0.350 EPS.

Definitive Healthcare Price Performance

NASDAQ:DH traded down $0.07 during trading hours on Friday, hitting $4.24. The stock had a trading volume of 1,200,343 shares, compared to its average volume of 326,752. The firm has a market capitalization of $500.02 million, a price-to-earnings ratio of -1.22, a P/E/G ratio of 6.27 and a beta of 1.33. Definitive Healthcare has a one year low of $3.19 and a one year high of $10.62. The company has a 50 day simple moving average of $4.36 and a two-hundred day simple moving average of $4.98. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.40 and a quick ratio of 2.40.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Robert W. Baird decreased their price objective on shares of Definitive Healthcare from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. JPMorgan Chase & Co. cut shares of Definitive Healthcare from a “neutral” rating to an “underweight” rating and lowered their price objective for the company from $7.00 to $5.00 in a research report on Wednesday, July 31st. Morgan Stanley reduced their target price on Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. Deutsche Bank Aktiengesellschaft dropped their price target on Definitive Healthcare from $7.00 to $5.00 and set a “hold” rating for the company in a research note on Friday, August 9th. Finally, BTIG Research initiated coverage on Definitive Healthcare in a research report on Tuesday, September 17th. They set a “buy” rating and a $7.00 price objective on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.81.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.